Pharmaceuticals

Bristol Myers Squibb

Bristol-Myers Squibb Sees Surge in Call Options, Beats Earnings Expectations with Upgraded Ratings

BMS Announces Izalontamab Brengitecan Shows Survival Benefit in TNBC and ESCC and Receives Priority Review in China

Piper Sandler Reaffirms Buy Rating on BMS with $75 Price Target

FDA Accepts BMS Camzyos Supplemental NDA for Adolescents and Grants Priority Review

Bristol-Myers Squibb's Opdivo Receives EU Label Extension for First-Line Treatment of Advanced Classical Hodgkin Lymphoma

Bristol Myers Squibb Partners with Anthropic and Tempus AI to Build AI Drug Development Collaboration

Bristol Myers Squibb Provides Anthropic's Claude to 30,000 Employees

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Bristol Myers Squibb Shareholders Approve Management Proposals and Reject Independent Chairman Proposal

LJI Wealth Management LLC Buys More Shares of Bristol-Myers Squibb

Scotiabank Analyst Maintains Hold Rating for BMY

Robertson Stephens Increases Holdings in Bristol Myers Squibb

GC Wealth 大幅减持百时美施贵宝持股

Artemis Investment Management Increases Holdings in Bristol-Myers Squibb

Bristol Myers Squibb released FY2026 Q1 earnings on April 30 During-Market (EST), actual revenue USD 11.49 B (forecast USD 10.92 B), actual EPS USD 1.31 (forecast USD 1.1501)

Bristol Myers Squibb Reports Q1 EPS Exceeding Expectations

Bristol-Myers Squibb Exceeds Revenue Expectations in Q1

Bristol-Myers Squibb reports Q1 gross margin of 70.2%

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

Bristol Myers Squibb (BMY) shares rose 1.64% to $56.48 on Tuesday, outperforming the S&P 500 but underperforming key competitors like Johnson & Johnson and Pfizer. Trading volume exceeded its 50-day average. The stock remains 10.19% below its 52-week high of $62.89 reached in March.

MarketWatch Automated

Dow Jones Industrial Average

S&P 500

Johnson & Johnson

Pfizer

Abbott Laboratories

Factset Research

Bristol-Myers Squibb Company

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Bristol-Myers Squibb (BMY) stock fell 3.00% on June 8, underperforming its sector due to generic competition eroding revenue from key drugs like Revlimid and conservative earnings guidance. While pipeline advancements such as FDA Priority Review for Camzyos and positive Phase 3 results offer future growth, immediate financial pressures dominate sentiment. Analysts maintain a 'Hold' rating with an average price target of $62.06, though institutional confidence waned with Capital International reducing holdings by 35.2%. Technical indicators show mixed signals.

TradingKey

Eli Lilly

Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis

INTC

MRVL

KLAC

AMAT

WELL

Intel(INTC) rose 11.19%, with a trading turnover 15.0 Billion USD, and a year-to-date rose 198.8%. Micron Tech(MU) rose 9.87%, with a trading turnover 50.6 Billion USD, and a year-to-date rose 232.7%. Novo Nordisk AS(NVO) fell 4.52%, with a trading turnover 856.8 Million USD, and a year-to-date fell 16.6%. Welltower Op(WELL) fell 3.35%, with a trading turnover 585.3 Million USD, and a year-to-date rose 8.5%.

- The Nasdaq Composite Index increased by 0.86%, with a year-to-date gain of 11.6%.  
- Intel (INTC) rose by 11.19%, achieving a year-to-date increase of 198.8% with a trading volume of $15 billion.  
- Micron Technology (MU) saw a 9.87% rise, with a year-to-date gain of 232.7%, while Novo Nordisk (NVO) fell by 4.52%, posting a year-to-date drop of 16.6%.

Top Gainers&Losers

Intel

Micron Tech

Marvell Tech

Applied Materials

Novo Nordisk AS

Welltower Op

Sanofi

Top 5 US Stock Gainers/Losers (>100B) (6.8)

Bristol Myers Squibb (BMY) shares fell 2.97% to $55.57 on Monday, underperforming competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories. The decline ended a three-day winning streak, with the stock trading 11.63% below its 52-week high of $62.89. Trading volume reached 11.9 million, exceeding the 50-day average.

Bristol Myers Squibb Co. Stock Underperforms Monday When Compared To Competitors

AVGO

An analyst revised Stock Grader recommendations for 142 blue-chip stocks based on institutional buying pressure and fundamental health. Key changes include upgrading Bristol-Myers Squibb from Neutral to Strong and downgrading Broadcom from Strong to Neutral. Other notable adjustments involve upgrades for Arrow Electronics and downgrades for Albemarle, reflecting updated quantitative and fundamental grades across various sectors.

InvestorPlace

Arrow Electronics

Broadcom

Albemarle

Invesco PHLX Semiconductor ETF

VanEck Semiconductor ETF

iShares Semiconductor ETF

Direxion Semicon Bull 3X

SPDR S&P Semicon

Invesco Semiconductors ETF

First Trust Nasdaq Food & Semicon

Roundhill AVGO WeeklyPay ETF

Leverage Shares 2X Long AVGO Daily ETF

Direxion Daily AVGO Bull 2X Shares

Defiance Daily Target 2X Long AVGO ETF

GraniteShares 2x Long AVGO Daily ETF

Direxion Daily AVGO Bear 1X Shares

Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks

Bristol Myers Squibb (BMY) launched the 'Investigating Myeloma' awareness campaign in partnership with Mariska Hargitay to honor her father, who died from multiple myeloma 20 years ago. The campaign highlights unmet needs in treating the disease and promotes CELMoD research, a targeted protein degradation approach led by BMS that aims to enhance cancer cell killing and renew hope for patients.

StockTitan

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease | BMY Stock News

Bristol Myers Squibb (BMY) shares rose 1.18% to $57.27 on Friday, marking its third consecutive day of gains despite a broader market decline where the S&P 500 and Dow Jones fell. However, BMY underperformed compared to key competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories, which all posted higher percentage increases. The stock remains 8.93% below its 52-week high.

News

News Corporation Shs B Chess Depository Interests repr 1 Sh

News Corporation Shs A Chess Depository Interests repr 1 Sh

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Bristol Myers Squibb(BMY.US)